W

bioLLM/wiki

LLM-Synthesized Biotech Database

Live

Ranibizumab

Ranibizumab

Overview

Ranibizumab is an intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy used in retinal disease, particularly conditions driven by pathologic neovascularization and vascular leakage. It is a monoclonal antibody fragment designed to bind VEGF-A and thereby reduce abnormal blood vessel growth and vascular permeability in the eye. In clinical practice, it is administered by intraocular injection and is widely used in neovascular retinal disorders, including age-related macular degeneration and myopic choroidal neovascularization.

Biologically, ranibizumab acts at the level of VEGF-mediated signaling, a pathway central to exudation and neovascular complications in diseases such as diabetic macular oedema, retinal vein occlusion, central serous chorioretinopathy, and choroidal neovascularization. Recent research continues to position anti-VEGF therapy as first-line treatment in several of these disorders, while also examining variability in response, long-term outcomes, and pharmacokinetics within the human eye.

Recent Publications Focus

Below is a summary of the newest research publications targeting Ranibizumab (sorted by publication date).

  • Ten-year outcomes of intravitreal injection of ranibizumab for the treatment of myopic choroidal neovascularization (PMID: 42175486, Medicine, 2026-05-22)
    This long-term study evaluated the efficacy and 10-year outcomes of intravitreal ranibizumab for myopic choroidal neovascularization (CNV). The publication specifically focused on sustained clinical performance over a decade, supporting ranibizumab’s role as a durable anti-VEGF therapy in a neovascular retinal disease driven by abnormal choroidal vessel growth. The study design centered on intravitreal injection, emphasizing real-world ophthalmic delivery and long-term follow-up of treatment effect.

  • Analysis of the therapeutic effects of anti-vascular endothelial growth factor treatment based on indocyanine green angiographic staining patterns in patients with central serous chorioretinopathy (PMID: 42192607, Indian journal of ophthalmology, 2026-06-01)
    This study examined whether indocyanine green angiography (ICGA)-based gray-level co-occurrence matrix texture analysis could predict response to anti-VEGF treatment in central serous chorioretinopathy (CSC). Although the publication is framed around anti-VEGF therapy rather than ranibizumab alone, it is directly relevant to ranibizumab as a representative anti-VEGF agent used in retinal disease. The work linked imaging biomarkers from ICGA with therapeutic response, suggesting that structural staining patterns may help identify patients more likely to benefit from VEGF-targeted treatment.

  • Efficacy and safety of anti-VEGF monoclonal antibody 601 for macular oedema in retinal vein occlusion: two phase IIa randomised clinical trials (PMID: 41448868, The British journal of ophthalmology, 2026-06-22)
    This publication investigated a novel anti-VEGF monoclonal antibody in macular oedema secondary to retinal vein occlusion (RVO), including branch RVO and central RVO. While not a ranibizumab trial, it is relevant because ranibizumab is a standard anti-VEGF comparator and established treatment in this disease area. The study underscores the continuing need for additional treatment options beyond current VEGF-targeted therapies and reflects the broader therapeutic context in which ranibizumab is used.

  • Baseline microperimetry and metabolic status predict functional outcomes in diabetic macular oedema: a prospective cohort study of anti-VEGF therapy (PMID: 42358096, Annals of medicine, 2026-06-26)
    This prospective cohort study assessed whether baseline microperimetry and metabolic status could predict functional outcomes in diabetic macular oedema treated with anti-VEGF therapy. Ranibizumab is relevant here as part of the anti-VEGF class used as first-line treatment in diabetic macular oedema. The study highlights the importance of functional testing, including microperimetry, and systemic metabolic context in anticipating treatment response, rather than relying solely on anatomical retinal changes.

  • Nationwide trends and regional variation in intravitreal injections and anti-VEGF agent use in Japan from 2017 to 2022: An analysis of the NDB Open Data (PMID: 42096458, PloS one, 2026-01-01)
    This population-level analysis used Japanese NDB Open Data and procedure code G016 to quantify intravitreal injection procedures and drug-specific use of aflibercept, ranibizumab, brolucizumab, and faricimab. The study provides utilization context for ranibizumab within national anti-VEGF prescribing patterns, showing how it is tracked alongside newer agents in routine ophthalmic care. Such data are useful for understanding treatment adoption, regional variation, and shifts in anti-VEGF practice over time.

  • Computational modeling of intravitreal ranibizumab kinetics: Predicting macular drug concentration and half-life (PMID: 42096431, PloS one, 2026-01-01)
    This study used COMSOL Multiphysics 6.3 to model intravitreal ranibizumab kinetics in the human eye, with attention to macular drug concentration and half-life. The modeling incorporated transport of diluted species and Darcy’s law, reflecting a mechanistic approach to ocular pharmacokinetics. The work is directly centered on ranibizumab and addresses a key clinical issue in anti-VEGF therapy: how intraocular distribution and clearance influence treatment durability and injection frequency in neovascular retinal diseases.

  • Iron Homeostasis Restoration via Triple-Pool-Targeted Nanotherapy for Enhanced Amelioration of Age-Related Macular Degeneration (PMID: 42054488, ACS nano, 2026-05-12)
    This publication discussed age-related macular degeneration (AMD) as a disease in which current clinical treatment is predominantly dependent on intravitreal anti-VEGF administration targeting late-stage choroidal neovascularization. Ranibizumab is part of this established anti-VEGF treatment paradigm. The paper’s broader context emphasizes limitations of anti-VEGF monotherapy, including incomplete response and adverse effects, and positions ranibizumab within the standard therapeutic framework that newer approaches aim to complement or improve upon.

Background PMIDs

  • [PMID 41448868]

Method PMIDs

  • [PMID 42054488]

Target PMIDs

  • [PMID 42358096]
  • [PMID 41448868]
  • [PMID 42192607]
  • [PMID 42175486]
  • [PMID 42096458]
  • [PMID 42096431]
Content is generated using Large Language Models (LLMs) and may contain errors or hallucinations. Experts periodically review it to verify accuracy and maintain database integrity.